NCT06429566Active, not recruitingPhase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Oral Local Use of GB001 Recombinant Peptide Spray for the Treatment of Mild Recurrent Aphthous Ulcer
Zhejiang Echon Biopharm Limited1 site in 1 country120 target enrollmentStarted: July 18, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Target ulcer healing rate for patients in day 6
Study Overview
Brief Summary
This trial is conducted in China. The purpose is to evaluate the efficacy, Pharmacokinetics (PK) profile, immunogenicity and safety of GB001 recombinant peptide spray in adults with mild recurrent aphthous ulcer.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •It meets the diagnostic criteria for mild recurrent Aphthous ulcer in the fifth edition of Oral Mucosa published by People's Medical Publishing House in
- •18≤ age ≤65 years old, gender is not limited.
- •Patients with untreated target ulcer onset ≤48 hours at the time of screening.
- •VAS score of target ulcer irritation pain ≥3 points, 2mm≤ length diameter of target ulcer ≤10mm.
- •Subjects and their sexual partners agree to use effective contraception during the study period and for at least 30 days after the study ends.
- •Sign a written informed consent, and be able to comply with the visit and related procedures stipulated in the program.
- •Exclusion criteria:
- •The diagnosis was severe aphthous ulcer, herpetic aphthous ulcer, acute herpetic gingivitis stomatitis, traumatic ulcer, cancerous ulcer, tuberculous ulcer, syphilitic ulcer, necrotic salivate metaplasia, Behcet disease and other diseases or drug induced ulcers.
- •Patients with suppurative tonsillitis or other painful lesions in the mouth, such as pericoronitis, pulpitis, periapical inflammation, etc., affecting the pain score of target ulcer.
- •Target ulcer is affected by residual root, residual crown, denture, prosthesis, orthodontic device and other stimulating factors in the corresponding parts of the target ulcer.
- •The ulcer is located in the lingual frenulum, the back wall of the pharynx and other parts, and its size is not easy to measure.
- •Those who plan to perform other oral treatments during the trial that affect the determination of drug effectiveness and safety.
- •Smokers > 20 cigarettes/day or betel nut lovers in the past 3 months.
- •People who have used painkillers or drugs that may affect the efficacy of pain observation within 24 hours before the first administration, such as sedatives, anti-allergy drugs, non-steroidal anti-inflammatory drugs, etc.
- •Patients who have used antibiotics or antiviral drugs locally or systematically within 1 week before screening.
- •Patients who had used immunosuppressive agents locally within 1 week before screening or systemic immunosuppressive agents within 2 weeks before screening.
- •Patients with oral local or systemic use of glucocorticosteroids within 4 weeks prior to screening.
- •Patients who have taken anticholinergic drugs to reduce salivary secretion within 2 weeks prior to screening.
- •Complicated with severe liver and kidney diseases, or abnormal liver and kidney function tests (ALT and AST≥ 1.5 times the upper limit of normal, SCr > the upper limit of normal).
- •Patients with severe anemia (Hb < 60g/L).
- •Complicated with severe heart and lung disease, uncontrolled diabetes (fasting blood glucose > 7.0mmol/L or random blood glucose ≥11.1mmol/L), advanced tumors, diseases of the blood and hematopoietic system, or other serious or progressive diseases of the system.
- •Known or suspected allergic history or serious adverse reactions to the experimental drug and its excipients.
- •Pregnant or lactating women and those with recent pregnancy plans.
- •Participants who had participated in other interventional clinical trials within 3 months prior to screening.
- •Other conditions deemed inappropriate by the investigator for participation in the study.
Exclusion Criteria
- Not provided
Arms & Interventions
GB001 recombinant peptide spray low dose group
Experimental
Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray.
Intervention: GB001 recombinant peptide spray low dose group、high dose group (Drug)
GB001 recombinant peptide spray high dose group
Experimental
Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.216mg/spray.
Intervention: GB001 recombinant peptide spray low dose group、high dose group (Drug)
Placebo group
Experimental
Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, for 8 days.
Intervention: GB001 recombinant peptide spray placebo (Drug)
Outcomes
Primary Outcomes
Target ulcer healing rate for patients in day 6
Time Frame: Day 6
Ulcer healing was defined as disappearance of pain and zeroing of ulcer size. At the screening visit the ulcer area and pain severity of patient to clinical examination will be rated at baseline. The patients will be self-assessment pain severity in vas score sheet every day . And the patients will be re-examined in day 6 to assess the ulcer area by periodontal probe.
Subjects self-rated the time it took for irritation pain to disappear
Time Frame: Day 8
Secondary Outcomes
- Time for target ulcer to heal(Day 8)
- Immunogenicity(drug resistant antibody (ADA))(Day 1,Day 14,Day 28)
- Targeted ulcer healing rate for patients in day 4 and day 8(Day 4,Day 8)
- Pharmacokinetics Characteristics， Cmax of GB001 Recombinant Peptide(Day 1,Day 4)
- Pharmacokinetics Characteristics， Tmax of GB001 Recombinant Peptide(Day 1,Day 4)
- Pharmacokinetics Characteristics， t½ of GB001 Recombinant Peptide(Day 1,Day 4)
- Pharmacokinetics Characteristics，AUC of GB001 Recombinant Peptide(Day 1,Day 4)
- Incidence of Adverse Events(First dose to last visit,an average of 1 month.)
- Changes in target ulcer area relative to baseline(Day 4,Day 6,Day 8)
- Self evaluation of pain disappearance rate and relief rate(Day 4,Day 6,Day 8)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy SubjectsHealthyNCT05125211Zhejiang Echon Biopharm Limited91
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese VolunteersHealthyNCT02746302Jiangsu Hansoh Pharmaceutical Co., Ltd.62
Completed
Phase 1
The Safety, Tolerability and Pharmacokinetic Study of RAY1225ObeseHealthyNCT05835752Guangdong Raynovent Biotech Co., Ltd68
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese VolunteersHealthyNCT02746315Jiangsu Hansoh Pharmaceutical Co., Ltd.40
Completed
Phase 1
Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese SubjectsHealthyDiabetesNCT01868555Novo Nordisk A/S32